Agenda

8:30 AM

Registration & Welcome coffee

9:30 AM

Opening remarks

Pedro Coelho

CEO, Biorce

9:35 AM

Welcome

A word on the host hospital’s work, and where the day’s contribution goes.

Joana Claverol

Sant Joan de Déu Research Foundation

9:45 AM

| Opening keynote

AI and the Future of Scientific Judgement

Where does human judgement still belong once AI can draft the protocol, choose the sites, and read the data. An opening argument for what we should, and should not, hand over.

TBC

10:15 AM

| Panel

Protocols as Data

What changes when the protocol stops being a document and becomes structured, queryable data. The design decisions that get easier, the ones that get harder, and what it takes to work this way in practice.

Shenika Vilton

Sr Clinical Specialist

Moderator

Hugh Levaux

Consultant and Board Member for HSBI, LLC

Jonathan Crowther

Head, Operational Design Center at Merck Healthcare KgaA

Zak Smith

Assistant Director, Data Sciences & Analytics at Tufts CSDD

11:00 AM

Morning Break

11:30 AM

| Podium

From Mandate to Adoption

Buying a platform is the easy part. A buyer’s-eye view of what it takes to get one adopted across an R&D organisation: aligning stakeholders, weighing a top-down mandate against bottom-up buy-in, and meeting what the head of R&D actually needs.

Barry Cymerman

Associate Director, Global Category Management | R&D Procurement

11:55 AM

| Panel

The Next CRO Operating Model

The sponsor and CRO relationship was built for a slower era. What the operating model looks like when AI and data change who does what, and where the real leverage sits now.

Craig Lipset

Managing Partner, Clinical Innovation Partners

Moderator

Speaker to be announced

12:40 PM

| Podium

Site Burden & Decentralized Clinical Trial

Running decentralised trials where reaching patients is hardest. What Sant Joan de Déu has learned about lowering the burden on families without lowering the standard of the science.

Joana Claverol

Sant Joan de Déu

1:00 PM

Lunch and networking

2:15 PM

| Podium

Where Trial Innovation Dies

Most trial innovation does not fail in the lab. It dies in the gap between a good idea and operational reality. A candid look at where, and why, and what survives contact with a live trial.

Craig Lipset

Managing Partner, Clinical Innovation Partners

2:45 PM

| Panel

Signal, Hype, and Governance

What AI is genuinely delivering in trials today versus what is still demo theatre, and then the harder question: who is accountable when a model is in the loop, both in the room and in front of a regulator.

Willem Baralt

Portfolio Chair & Independent Board Director

Moderator

John E Milad

CEO at ERS Genomics

Alex Turpin

Senior Director at AI Governance & Enablement

3:30 PM

Afternoon break

3:55 PM

| Panel

Can Europe Still Compete? Bringing the Pivotal Trial Home

Pivotal trials have drifted away from Europe. What it would take to bring them back, and whether the region can still compete on speed, cost, and patient access.

Lucilla Guidotti

Scientific Communications Team Lead

Moderator

Graham Belgrave

Managing Director-International, Executive Coach and Mentor

William Hariri

Biotech Entrepreneur

4:35 PM

| Platform Demonstration

Aika 2.0

A first look at Aika 2.0, and where Biorce is taking it next.

Clara Bernardes

Co-Founder & Chief Scientific Officer at Biorce

4:50 PM

| Closing fireside

The Human Cost of Slow Medicine

Victoria Gray was the first person treated with CRISPR for sickle cell disease, and her host, Magda Kurtz, has been a patient in clinical research herself. A conversation between two people who have lived the waiting, about what the years between a breakthrough and a patient reaching it really cost, and why the pace of this work matters.

Victoria Gray

Advocate and First CRISPR Gene Therapy Recipient for SCD

Magda Kurtz

Sr Director of Clinical Solutions – Europe at Biorce

5:30 - 7:00 PM

Networking Reception